# US Carrier Screening Market > US Carrier Screening Market Research Report By Test Type (Single Gene Testing, Panel Testing, Expanded Carrier Screening), By Technology (Next Generation Sequencing, Polymerase Chain Reaction, Sanger Sequencing), By Application (Prenatal Screening, Preconception Screening, Newborn Screening) and By End User (Hospitals, Diagnostic Laboratories, Research Institutions) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.83% - **2024:** $ 1,495.68 Million - **2025:** $ 1,627.74 Million - **2035:** $ 3,793.16 Million - **Key Players:** Invitae (US), Myriad Genetics (US), Fulgent Genetics (US), Natera (US), GeneDx (US), Ambry Genetics (US), Quest Diagnostics (US), Laboratory Corporation of America (US) **Report ID:** MRFR/Pharma/15205-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-carrier-screening-market-16733 --- ## Market Summary ## **US Carrier Screening Market Overview** As per MRFR analysis, the US Carrier Screening Market Size was estimated at 1.37 (USD Billion) in 2023. The US Carrier Screening Market Industry is expected to grow from 1.49(USD Billion) in 2024 to 3.79 (USD Billion) by 2035. The US Carrier Screening Market CAGR (growth rate) is expected to be around 8.84% during the forecast period (2025 - 2035). ### **Key US Carrier Screening Market Trends Highlighted** The US Carrier Screening Market is experiencing growth driven by several key market drivers, including the increasing prevalence of genetic disorders and a rising awareness among healthcare professionals and patients regarding the importance of genetic testing. With advancements in technology, such as next-generation sequencing, testing has become faster and more accessible. Many states in the US are pushing for expanded carrier screening as part of standard prenatal care, leading to a significant shift in acceptance among both providers and patients. There are opportunities to be explored in the area of personalized medicine. As healthcare focuses more on individualized treatment plans, the demand for carrier screening will likely increase, enabling better-informed reproductive choices. Additionally, educational programs aimed at increasing public knowledge of genetic disorders can help foster an environment where carrier screening is seen as a normal part of healthcare. Recent trends indicate a growing emphasis on integrating carrier screening into routine healthcare protocols. The rise of telehealth services has also made it easier for patients to consult with genetic counselors, facilitating discussions about carrier screening. The health insurance landscape is evolving, with more policies beginning to cover genetic testing, which further supports access to these services. As the regulatory framework in the US adjusts to accommodate new technologies and practices, the Carrier Screening Market is poised for further development, leveraging these trends to enhance patient care and service availability. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Carrier Screening Market Drivers** ### **Increased Awareness about Genetic Disorders** The rising awareness regarding genetic disorders and the benefits of carrier screening in preventing genetically transmitted diseases is one of the significant drivers for the US Carrier Screening Market Industry. According to the US Centers for Disease Control and Prevention (CDC), about 1 in 33 babies is born with a birth defect. With such alarming statistics, health campaigns and educational programs led by organizations like the American College of Obstetricians and Gynecologists (ACOG) have been instrumental in emphasizing the importance of screening. Furthermore, the increase in awareness is prompting more parents to seek genetic testing before or during pregnancy, thus stimulating the growth of the market. As technology advances, screening processes are becoming more accessible, integrated into routine check-ups, and affordable, providing a robust growth trajectory for the US Carrier Screening Market Industry in the coming years. ### **Technological Advancements in Genetic Testing** Technological innovations in genetic testing methods such as Next Generation Sequencing (NGS) and improvements in bioinformatics tools are significant drivers for the US Carrier Screening Market Industry. The advent of these technologies has dramatically reduced the costs and time associated with genetic testing. According to the National Institutes of Health (NIH), the cost of sequencing a human genome has dropped from approximately $100 million in 2001 to about $1,000 today. Leading companies like Illumina and Thermo Fisher Scientific have been at the forefront of these advancements, ensuring that carrier screening becomes increasingly reliable and widespread. This continued innovation will directly boost the adoption rates of carrier screening in the United States. ### **Growing Demand for Personalized Medicine** The increasing shift towards personalized medicine is propelling the demand for carrier screening in the US Carrier Screening Market Industry. As healthcare moves towards more individualized treatment plans, understanding a patient's genetic makeup becomes essential. A report from the National Institutes of Health reveals that more than 80 percent of chronic diseases have a genetic component, underscoring the demand for personalized approaches. Organizations such as the FDA are encouraging this movement by approving drugs and therapies based on genetic profiles. Therefore, as more healthcare providers integrate personalized medicine into their practices, the need for genetic carrier screening is expected to surge, significantly impacting the growth of the market. ### **Government Initiatives Supporting Genetic Testing** Government initiatives aimed at improving maternal and child health through genetic testing significantly influence the US Carrier Screening Market Industry's growth. Federal programs under the Maternal and Child Health Bureau are promoting awareness and access to carrier screening, enhancing the number of individuals who opt for genetic tests. According to the Health Resources and Services Administration (HRSA), investments in public health initiatives have increased funding by over 15% in the last five years for genetic screening. These policies not only enhance the field's reputation and legitimacy but also encourage more healthcare professionals to recommend screening. With continued governmental support, the accessibility and awareness of carrier screening are likely to expand, driving further market growth. ## **US Carrier Screening Market Segment Insights** ### **Carrier Screening Market Test Type Insights** The Test Type segment of the US **[Carrier Screening Market](../../../reports/carrier-screening-market-8755)** provides critical insights into the various methodologies employed for genetic testing. This market segment is essential as it enables healthcare professionals to identify potential carriers of genetic disorders and assess the risk of passing these conditions to offspring. The US regulatory environment is evolving to keep pace with these advancements, ensuring that testing remains safe, effective, and accessible. Each of these Test Type categories contributes significantly to the growth and development of the US Carrier Screening Market, addressing an increasing need for advanced genetic insights among the population. The growing acceptance of carrier screening as a standard practice in reproductive planning illustrates the market's evolution and its increasing relevance in healthcare, particularly in the US. The US Carrier Screening Market continues to thrive on the basis of these diverse testing methodologies, ensuring that individuals have access to crucial genetic information that can shape their family planning choices. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Carrier Screening Market Technology Insights** The Technology segment of the US Carrier Screening Market encompasses several advanced methodologies that are essential for genetic analysis and screening processes. Among these, Next Generation Sequencing (NGS) stands out as a powerful tool that allows for comprehensive analysis of genetic information, thus significantly enhancing the accuracy of carrier screening. The increasing prevalence of genetic disorders in the US has driven demand for these technologies, as healthcare providers emphasize early detection and prevention. Additionally, advancements in technology and growing awareness of carrier screening's importance among patients are accelerating the adoption of these testing methods. This market segment is characterized by rapid developments and innovations aimed at improving accuracy and turnaround times, reflecting the overarching trends towards personalized medicine and targeted therapies. As such, the Technology segment plays a pivotal role in the overall landscape of the US Carrier Screening Market, offering critical solutions to meet the needs of both healthcare providers and patients. ### **Carrier Screening Market Application Insights** The Application segment of the US Carrier Screening Market plays a crucial role in identifying genetic disorders prevalent in various populations. This sector comprises different screening approaches, including Prenatal Screening, Preconception Screening, and Newborn Screening. Overall, the US Carrier Screening Market segmentation reflects growing awareness and adoption of genetic screening as a preventive healthcare measure, driven by advancements in technology, a focus on personalized medicine, and the increasing prevalence of genetic disorders. As the market evolves, regulatory support and public education will also play essential roles in expanding the reach and acceptance of these applications, ultimately benefiting families and healthcare providers across the United States. ### **Carrier Screening Market End User Insights** The US Carrier Screening Market encompasses various end users including Hospitals, Diagnostic Laboratories, and Research Institutions, each playing a critical role in the industry. Hospitals are significant players in this segment as they provide comprehensive healthcare services, integrating carrier screening into routine genetic testing for patient management and counseling. Diagnostic Laboratories are equally vital, specializing in genetic tests that help in identifying carrier status for inherited conditions, thus supporting physicians and patients with precise information for decision-making. Research Institutions contribute essential advancements in the field by conducting studies that enhance the understanding of genetic disorders and the development of new testing methodologies. The growing awareness of genetic conditions and the importance of preconception screening are creating substantial opportunities within the market, driven by the need for personalized medicine and early intervention strategies. Moreover, federal and state initiatives backing genetic testing underscore the relevance of this market segment. Overall, the end user category of the US Carrier Screening Market is characterized by a collaborative approach aimed at improving public health through informed genetic insights. ## **US Carrier Screening Market Key Players and Competitive Insights** The US Carrier Screening Market is a rapidly evolving segment within the broader healthcare landscape, driven by advancements in genetic testing technologies and increasing consumer awareness of genetic disorders. It serves a critical role in preconception planning and prenatal care, enabling prospective parents to understand their genetic makeup and potential risks for inherited conditions. With the rise of personalized medicine and an emphasis on preventive healthcare, the demand for carrier screening tests has escalated. This has led to a competitive environment characterized by several key players that offer a range of tests, including single-gene tests and expanded carrier panels. Companies in this market leverage technology, partnerships, and innovative solutions to gain market share and provide comprehensive services to healthcare providers and patients alike. LabCorp is a significant player in the US Carrier Screening Market, recognized for its broad testing capabilities and extensive experience in laboratory services. The company boasts a strong presence across the United States, with a network of laboratories and patient service centers that facilitate easy access to carrier screening tests. LabCorp's strengths lie in its robust portfolio of genetic testing options and a commitment to high-quality laboratory standards. The company’s ability to integrate advanced testing technologies and its focus on delivering accurate results in a timely manner enhance its competitive edge. Furthermore, LabCorp continues to invest in research and development, aiming to expand its offerings and adapt to the evolving needs of healthcare providers and patients, solidifying its position as a trusted provider in the market. Fulgent Genetics is another influential entity within the US Carrier Screening Market, known for its innovative approach to genetic testing. The company offers a comprehensive array of tests tailored to carrier screening, including expansive panels that assess multiple genetic conditions in a single test. Fulgent Genetics has developed a reputation for its cutting-edge technology and quick turnaround times, which appeal to both healthcare practitioners and patients. The company’s strengths include its ability to customize testing solutions, ensuring that healthcare providers can obtain specific information relevant to their patient populations. Fulgent Genetics has also engaged in strategic mergers and acquisitions to enhance its market presence and broaden its product offerings. This dynamic approach, combined with a focus on improving the accessibility and affordability of genetic testing, has bolstered its standing within the US Carrier Screening Market, making it a notable competitor. ### **Key Companies in the US Carrier Screening Market Include** ## **US Carrier Screening Market Industry Developments** The US Carrier Screening Market is currently experiencing significant developments and growth, largely driven by advancements in genetic testing technologies and rising consumer awareness. Recent activities include LabCorp's continued expansion of its genetic testing services, as they emphasize personalized medicine. Myriad Genetics has also enhanced its portfolio, focusing on hereditary cancer testing alongside carrier screening, which reinforces their commitment to comprehensive patient care. Moreover, in September 2023, Fulgent Genetics announced an acquisition of a specialty laboratory specializing in reproductive health to broaden its carrier screening offerings. The merger activity signals a trend towards consolidation, aiming to leverage complementary technologies and improve market positioning. Additionally, Quest Diagnostics has increased its investments in digital health solutions, enhancing access to carrier screening tests for patients. Overall, the market is witnessing a market valuation growth in companies like Invitae and Color Genomics due to increased demand for genetic insights and preventative healthcare. In the past two years, noteworthy developments have included the introduction of expanded carrier screening panels, reflecting an ongoing trend towards more inclusive testing methodologies. ## **US Carrier Screening Market Segmentation Insights** ### **Carrier Screening Market Test Type Outlook** ### **Carrier Screening Market Technology Outlook** ### **Carrier Screening Market Application Outlook** ### **Carrier Screening Market End User Outlook** ## Market Drivers ### Rising Prevalence of Genetic Disorders The increasing prevalence of genetic disorders in the US population appears to be a significant driver for the carrier screening market. As more individuals are diagnosed with conditions such as cystic fibrosis and sickle cell disease, the demand for carrier screening tests is likely to rise. According to the CDC, approximately 1 in 25 individuals of Ashkenazi Jewish descent is a carrier for Tay-Sachs disease, highlighting the need for targeted screening. This growing awareness of genetic risks may lead to a greater emphasis on preventive healthcare measures, thereby expanding the carrier screening market. Furthermore, the integration of carrier screening into routine prenatal care could potentially enhance early detection and management of genetic conditions, fostering a more proactive approach to health in the US. ### Legislative Support for Genetic Testing Legislative initiatives aimed at supporting genetic testing and screening are likely to influence the carrier screening market positively. Recent policies in the US have focused on improving access to genetic testing services, particularly for underserved populations. For instance, some states have enacted laws mandating insurance coverage for carrier screening, which may alleviate financial barriers for patients. This legislative support could encourage more individuals to pursue carrier screening, thereby expanding the market. Additionally, public health campaigns promoting the importance of genetic testing may further raise awareness and acceptance among the general population. As these initiatives gain traction, the carrier screening market may experience increased growth and integration into standard healthcare practices. ### Growing Acceptance of Genetic Counseling The rising acceptance of genetic counseling services is emerging as a key driver for the carrier screening market. As more individuals seek guidance on genetic testing options, the role of genetic counselors becomes increasingly vital. These professionals help patients navigate the complexities of genetic information, ensuring that they understand the implications of carrier screening results. The National Society of Genetic Counselors reports a steady increase in the number of certified genetic counselors in the US, which may enhance the accessibility of these services. This trend suggests that as patients become more informed about their genetic health, the demand for carrier screening is likely to grow. Furthermore, the collaboration between healthcare providers and genetic counselors may facilitate a more comprehensive approach to patient care. ### Increased Focus on Preventive Healthcare The growing emphasis on preventive healthcare in the US is likely to bolster the carrier screening market. As healthcare systems shift towards value-based care, there is a heightened focus on early detection and intervention strategies. Carrier screening plays a crucial role in this paradigm by enabling individuals to understand their genetic risks and make informed reproductive choices. The US Preventive Services Task Force has recommended that all couples planning a pregnancy consider carrier screening for certain genetic conditions, which may further encourage uptake. This proactive approach to health management could lead to an increase in the number of individuals seeking carrier screening, thereby expanding the market. The integration of carrier screening into routine healthcare practices may also enhance patient engagement and awareness. ### Advancements in Genetic Testing Technologies Technological innovations in genetic testing methodologies are transforming the landscape of the carrier screening market. The advent of next-generation sequencing (NGS) has significantly improved the accuracy and efficiency of genetic tests, allowing for the simultaneous analysis of multiple genes. This advancement not only reduces the time required for testing but also lowers costs, making carrier screening more accessible to a broader population. As the price of genetic testing continues to decrease, it is projected that the market will experience substantial growth. The ability to provide comprehensive carrier screening panels that can identify a wide array of genetic conditions may further drive demand, as healthcare providers and patients increasingly recognize the value of early genetic insights. ## Future Outlook The [Carrier Screening Market](https://www.marketresearchfuture.com/reports/carrier-screening-market-8755) is projected to grow at 8.83% CAGR from 2025 to 2035, driven by technological advancements, increasing awareness, and rising demand for personalized medicine. **New opportunities:** - Development of AI-driven genetic analysis platforms Expansion of telehealth services for remote screening Partnerships with healthcare providers for integrated testing solutions By 2035, the carrier screening market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Test Type: Panel Testing (Largest) vs. Expanded Carrier Screening (Fastest-Growing) In the US carrier screening market, the market share is predominantly held by panel testing, which is favored for its comprehensive approach to detecting multiple genetic conditions simultaneously. Single gene testing, while still relevant, captures a smaller slice of the market as it only focuses on individual genes. This segmentation reflects varying preferences among healthcare providers and patients, with panel testing being the most sought-after method due to its efficiency and thoroughness. Growth trends indicate a significant rise in expanded carrier screening, which is becoming increasingly popular due to advancements in genetic technologies and heightened awareness among consumers about genetic conditions. Factors such as rising incidences of genetic disorders and the push for personalized medicine are driving this growth. Innovations and enhancements in testing capabilities further support the rapid adoption of expanded carrier screening, positioning it as a vital segment in the evolving landscape. Panel Testing (Dominant) vs. Single Gene Testing (Emerging) Panel testing is the dominant force in the US carrier screening market, recognized for its ability to screen for multiple genetic mutations across various conditions in a single test. This multifaceted approach not only enhances diagnostic accuracy but also streamlines the screening process for both patients and healthcare professionals. On the other hand, single gene testing, while categorized as emerging, remains valuable for specific cases where targeted screening is required. Often utilized for known familial conditions, it serves a critical purpose in the overall testing ecosystem, albeit with a narrowed focus compared to the comprehensive nature of panel testing. ### By Technology: Next Generation Sequencing (Largest) vs. Polymerase Chain Reaction (Fastest-Growing) In the US carrier screening market, Next Generation Sequencing (NGS) holds the largest market share among the technological advancements. Its ability to allow simultaneous analysis of numerous genes contributes significantly to its dominance. With an increasing number of laboratories adopting NGS technology, its market share has steadily expanded, marking it as a critical player in the industry. Conversely, Polymerase Chain Reaction (PCR) is identified as the fastest-growing segment. Its rapid and efficient processing capabilities make it preferred for specific applications, especially in situations requiring prompt results. Growth trends in this segment indicate a burgeoning demand driven by advancements in genetic testing and rising awareness regarding genetic disorders. The introduction of more accurate and accessible screening technologies is propelling the market forward. Additionally, governmental funding and initiatives aiming to enhance carrier screening accessibility are boosting the growth of Polymerase Chain Reaction, making it suitable for a wider demographic and ensuring its status as an emerging technology. Technology: NGS (Dominant) vs. PCR (Emerging) Next Generation Sequencing (NGS) is a dominant force within the technological landscape of the US carrier screening market, known for its unparalleled gene analysis capabilities and comprehensive data generation. This technology allows for the sequencing of entire genomes, thereby providing important insights into genetic predispositions that can affect health. Its adoption is widespread among genetic testing laboratories, making it a preferred choice for comprehensive carrier screening. In contrast, Polymerase Chain Reaction (PCR) stands as an emerging technology, characterized by its rapid amplification of DNA sequences, which is particularly advantageous in time-sensitive testing scenarios. The ability of PCR to deliver quick results makes it an increasingly popular choice among healthcare providers, catering to an urgent need for genetic testing in various applications. ### By Application: Prenatal Screening (Largest) vs. Newborn Screening (Fastest-Growing) In the US carrier screening market, the application segment is primarily dominated by prenatal screening, which holds the largest share due to increasing awareness about genetic disorders and advancements in testing technology. Newborn screening follows, supported by legislative mandates and growing parental awareness about early detection of genetic conditions. Growth trends in this segment indicate a robust increase in the adoption of advanced screening technologies. Prenatal screening is propelled by enhanced accessibility and public health initiatives. Conversely, newborn screening is recognized as the fastest-growing segment, driven by technological innovations and the need for timely intervention for genetic disorders, reflecting a growing commitment to preventative healthcare. Prenatal Screening: Dominant vs. Newborn Screening: Emerging Prenatal screening has established itself as a dominant force in the US carrier screening market, characterized by comprehensive tests that identify genetic risks during pregnancy. This segment benefits significantly from prenatal care practices and innovations that enhance testing accuracy and convenience. In contrast, newborn screening is emerging as a vital aspect of postnatal care. With advancements in testing methodologies and public health initiatives promoting early diagnosis, this segment is expanding rapidly. The technological evolution, coupled with heightened awareness of genetic conditions among new parents, positions newborn screening as a crucial component in safeguarding infants' health, catering to the increasing demand for early intervention and treatment options. ### By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing) The US carrier screening market exhibits a diverse distribution of end users, with hospitals commanding the largest share. Hospitals leverage advanced technologies and resources to perform carrier screenings, making them the primary choice for patients. In contrast, diagnostic laboratories are emerging rapidly as significant players, driven by increased demand for genetic testing and personalized medicine, positioning them for a larger market presence in the coming years. Growth trends in the end user segment indicate a robust expansion for diagnostic laboratories, which are capitalizing on the rising adoption of genetic screening protocols. Factors contributing to this growth include technological advancements in testing methods, government support for genetic initiatives, and a growing awareness among patients about the advantages of carrier screening. These dynamics create a competitive landscape where hospitals maintain their dominance while laboratories emerge as fast-growing alternatives. Hospitals: Dominant vs. Diagnostic Laboratories: Emerging Hospitals play a pivotal role in the US carrier screening market as they possess the infrastructure to conduct comprehensive genetic tests, providing a wide range of services under one roof. Their established relationships with patients and ability to integrate screenings into prenatal care enhance their market position. In contrast, diagnostic laboratories are considered emerging players, leveraging innovations in high-throughput screening and bioinformatics. They offer specialized services that cater to the growing demand for personalized genetic information among individuals. The focus of laboratories on efficiency and cutting-edge technology allows them to attract an increasing number of clients, posing a significant challenge to the traditional dominance of hospitals in the market. ## Competitive Benchmarking The carrier screening market is characterized by a dynamic competitive landscape, driven by advancements in genetic testing technologies and an increasing awareness of genetic disorders among prospective parents. Key players such as Invitae (US), Myriad Genetics (US), and Natera (US) are strategically positioned to leverage innovation and partnerships to enhance their service offerings. Invitae (US) focuses on expanding its genetic testing portfolio through acquisitions and collaborations, while Myriad Genetics (US) emphasizes the integration of artificial intelligence (AI) in its testing processes to improve accuracy and efficiency. Natera (US) is also notable for its commitment to digital transformation, utilizing advanced data analytics to refine its carrier screening solutions, thereby shaping a competitive environment that prioritizes technological advancement and customer-centric services.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with several players vying for market share, yet the collective influence of major companies like Quest Diagnostics (US) and Laboratory Corporation of America (US) contributes to a more concentrated competitive structure. These companies are not only expanding their testing capabilities but also enhancing their distribution networks to ensure broader access to carrier screening services. In October Invitae (US) announced a strategic partnership with a leading healthcare provider to integrate its genetic testing services into routine prenatal care. This collaboration is expected to streamline access to carrier screening for expectant parents, thereby potentially increasing the adoption of genetic testing in clinical settings. The strategic importance of this partnership lies in its ability to position Invitae (US) as a frontrunner in the prenatal genetic testing space, enhancing its market presence and customer engagement. In September Myriad Genetics (US) launched a new AI-driven platform designed to enhance the accuracy of its carrier screening tests. This innovative approach not only improves the reliability of test results but also reduces turnaround times, which is crucial in a market where timely information is paramount for decision-making. The introduction of this platform signifies Myriad's commitment to leveraging technology to differentiate its offerings in a competitive landscape. In August Natera (US) expanded its carrier screening services by introducing a comprehensive panel that covers a broader range of genetic conditions. This expansion is indicative of Natera's strategy to cater to a growing demand for more inclusive genetic testing options. By broadening its service offerings, Natera (US) aims to capture a larger share of the market, appealing to a diverse customer base seeking thorough genetic insights. As of November the carrier screening market is witnessing trends that emphasize digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are increasingly shaping the competitive landscape, fostering innovation and enhancing service delivery. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological innovation, reliability in supply chains, and the ability to provide comprehensive, accurate genetic testing solutions. ## Recent News & Developments The US Carrier Screening Market is currently experiencing significant developments and growth, largely driven by advancements in genetic testing technologies and rising consumer awareness. Recent activities include LabCorp's continued expansion of its genetic testing services, as they emphasize personalized medicine. Myriad Genetics has also enhanced its portfolio, focusing on hereditary cancer testing alongside carrier screening, which reinforces their commitment to comprehensive patient care. Moreover, in September 2023, Fulgent Genetics announced an acquisition of a specialty laboratory specializing in reproductive health to broaden its carrier screening offerings. The merger activity signals a trend towards consolidation, aiming to leverage complementary technologies and improve market positioning. Additionally, Quest Diagnostics has increased its investments in digital health solutions, enhancing access to carrier screening tests for patients. Overall, the market is witnessing a market valuation growth in companies like Invitae and Color Genomics due to increased demand for genetic insights and preventative healthcare. In the past two years, noteworthy developments have included the introduction of expanded carrier screening panels, reflecting an ongoing trend towards more inclusive testing methodologies. ## Report Scope | MARKET SIZE 2024 | 1495.68(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1627.74(USD Million) | | MARKET SIZE 2035 | 3793.16(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.83% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Invitae (US), Myriad Genetics (US), Fulgent Genetics (US), Natera (US), GeneDx (US), Ambry Genetics (US), Quest Diagnostics (US), Laboratory Corporation of America (US) | | Segments Covered | Test Type, Technology, Application, End User | | Key Market Opportunities | Advancements in genomic technologies enhance accuracy and accessibility in the carrier screening market. | | Key Market Dynamics | Technological advancements and regulatory changes drive growth in the carrier screening market, enhancing consumer access and awareness. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US carrier screening market?** A: The market valuation was $1495.68 Million in 2024. **Q: What is the projected market valuation for the US carrier screening market by 2035?** A: The projected valuation for 2035 is $3793.16 Million. **Q: What is the expected CAGR for the US carrier screening market during the forecast period 2025 - 2035?** A: The expected CAGR is 8.83% during the forecast period. **Q: Which companies are considered key players in the US carrier screening market?** A: Key players include Invitae, Myriad Genetics, Fulgent Genetics, Natera, GeneDx, Ambry Genetics, Quest Diagnostics, and Laboratory Corporation of America. **Q: What are the main segments of the US carrier screening market?** A: The main segments include Test Type, Technology, Application, and End User. **Q: What is the valuation range for Single Gene Testing in the US carrier screening market?** A: The valuation range for Single Gene Testing is $300.0 Million to $800.0 Million. **Q: How does Panel Testing perform in terms of market valuation?** A: Panel Testing has a valuation range of $600.0 Million to $1500.0 Million. **Q: What is the market valuation for Expanded Carrier Screening?** A: The valuation for Expanded Carrier Screening ranges from $595.68 Million to $1493.16 Million. **Q: Which technology segment has the highest valuation in the US carrier screening market?** A: Next Generation Sequencing has the highest valuation, ranging from $600.0 Million to $1500.0 Million. **Q: What is the expected market performance for prenatal screening applications?** A: Prenatal Screening is projected to have a valuation range of $600.0 Million to $1500.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-carrier-screening-market-16733*